SEC Contract Filing

Filing Date: 2018-05-15

Document Content:
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>pharmacyte_ex1002.htm
<DESCRIPTION>THIRD AMENDMENT TO LICENSING AGREEMENT
<TEXT>
<HTML>
<HEAD>
 <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="margin: 0"><B>Exhibit 10.2</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Third Amendment to Licensing Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Third Amendment
to the Licensing Agreement (&ldquo;<U>Third Amendment</U>&rdquo;) is effective on the date the parties have fully signed the Third
Addendum (&ldquo;<U>Effective Date of the Third Amendment</U>&rdquo;) and memorializes the agreement reached between PharmaCyte
Biotech, Inc., formerly Nuvilex, Inc. (&ldquo;<U>Licensee</U>&rdquo;), and Austrianova Singapore Pte Ltd (&ldquo;<U>Licensor</U>&rdquo;)
on 30 August 2017 relating to the Licensing Agreement between the Parties dated as of 1 December 2014, as amended by the First
Amendment to the Licensing Agreement dated as of June 30, 2015 and the Second Amendment to the Licensing Agreement dated as of
19 October 2015 (collectively, &ldquo;<U>Licensing Agreement</U>&rdquo;). Licensee and Licensor are referred to in this Third Amendment
individually as a &ldquo;<U>Party</U>&rdquo; and collectively as the &ldquo;<U>Parties</U>.&rdquo; Defined terms in the Licensing
Agreement have the same meaning in this Third Amendment as they do in the Licensing Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B><U>Recitals</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>A.</B></TD><TD STYLE="text-align: justify">The Parties entered into the Licensing Agreement to, among other things, provide Licensee with
an exclusive worldwide license to use the Cell-in-a-Box<SUP>&reg;</SUP> Trademark and its Associated Technology with genetically
modified non-stem cell lines specifically designed to activate members of the Cannabinoid family of molecules to conduct research,
to use in preclinical studies and clinical trials, to obtain marketing approval and to market and sell products and treatments
utilizing the Cell-in-a-Box<SUP>&reg;</SUP> Trademark and its Associated Technology world-wide;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>B.</B></TD><TD STYLE="text-align: justify">Section 3.1.1 of the Licensing Agreement provides that Licensee shall pay to Licensor royalties
equal to ten percent (10%) of Gross Sales Value of all Products sold by Licensee. The Parties desire to change the amount of royalties
Licensee shall pay to Licensor in accordance with the amended Section 3.1.1 below;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>C.</B></TD><TD STYLE="text-align: justify">Section 3.1.2 of the Licensing Agreement provides that Licensee shall pay to Licensor royalties
equal to twenty percent (20%) of the amount received by Licensee from Sub-Licensees on Sub-Licensees&rsquo; Gross Sales Value.
The Parties desire to change the amount of royalties Licensee shall pay to Licensor pursuant to Section 3.1.2 in accordance with
the amended Section 3.1.2. below;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>D.</B></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 3.2 of the Licensing Agreement provides Licensee shall pay Licensor certain milestone payments
upon the occurrence of certain events (&ldquo;Milestone Payments&rdquo;). The Parties desire to delete Section 3.2 in its entirety
from the Licensing Agreement;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>E.</B></TD><TD STYLE="text-align: justify">The Parties desire to add a new Section 3.2 to the Licensing Agreement in accordance with the new
Section 3.2 below;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in"><B>F.</B></TD><TD STYLE="text-align: justify">The Parties desire to add a new Section 10.6 to the Licen